Immunovaccine has announced successful immune responses from the Phase I clinical trial of a therapeutic cancer vaccine, DPX-0907.

The open-label, dose-escalating trial was conducted at five centres in the US, and evaluated the safety and immunogenicity of DPX-0907 vaccine in patients with advanced stage breast, ovarian or prostate cancer.

The data confirms the activity of the drug in humans and its potential to enhance immune responses to peptide vaccines.

Immunovaccine chief science officer and chief operating officer Marc Mansour said the vaccine targets specific T cells displaying multiple activation markers, and in turn these polyfunctional T cells target cancer cells.